Analytic morphomics is a novel methodology that uses highthroughput computed tomography (CT) processing techniques to generate reproducible body measurements (Supplementary  Table) . [1] [2] [3] [4] Body mass index is widely used in clinical and public health studies to predict mortality risk. 5 Indeed, we recently examined its impact in allogeneic hematopoietic cell transplantation (HCT) and found that obese patients were at significantly greater risk of mortality compared with normal weight individuals. 6 Unfortunately, body mass index does not reliably distinguish adipose tissue mass from muscle mass. 7 Therefore, we sought to index patient size using CT measurements. 2 The aim of the current study was to apply analytic morphomics in a cohort of allogeneic HCT patients and correlate with clinical outcomes.
Through retrospective cross-referencing of HCT and radiological databases between 1 January 2004 and 31 July 2014, we identified 256 patients who had complete demographic data and archived CT scans within 6 months of allogeneic HCT. The scans were retrieved, de-identified and processed. Only one scan, closest to the HCT date, was used per patient. All CT scans were performed at the University of Michigan and were not performed specifically for the purpose of this study, which was approved by the Institutional Review Board.
Analytic morphomics was performed using proprietary, semiautomated high-throughput CT image processing programmed in MATLAB R2014b (version 13.0, MathWorks Inc., Natick, MA, USA). [1] [2] [3] [4] The user identified locations of each vertebral level on each patient's CT scan, and each de-identified scan was further visually examined and processed, as necessary, by another researcher for quality assurance. This 'anatomic indexing' by vertebral level served as an anatomical reference system to enable precise measurements standardized for each patient (Figure 1a ). Once the anatomic indexing was completed, the user defined key anatomic landmarks within the linea alba from T7 to L5 vertebral points. The MATLAB algorithm then automatically generated the facial envelope and skin morphomic measurements (Figure 1b) . Similarly, after the user defined the lateral seams of the erector spinae muscles at specified vertebra points, the dorsal muscle group (DMG) measures were automatically generated ( Figure 1c) . 1 Between the thoracic and lumbar vertebral levels T7 and L5 studied, the vertebral level T12 was visible in the greatest number of eligible CT scans. Therefore, in our study population, analytic morphomic measurements collected at T12 levels were retrieved for subsequent analyses and compared across individuals.
Within the fascial envelope and skin contours, the subcutaneous region was defined as the region deep to the patient's skin and superficial to an envelope of fascial tissue separating the visceral and subcutaneous regions (Figure 1d ). 4 Subcutaneous adipose tissue (SAT) area was defined as the cross-sectional area (mm 2 ) of fat-intensity pixels (−205 to − 51 Hounsfield Unit (HU) 3, 8 ) within the subcutaneous region. Visceral adipose tissue (VAT) area was defined as the cross-sectional area (mm 2 ) of fat-intensity pixels within the visceral cavity (defined by the superficial fascial envelope). Fascia area was defined as the cross-sectional area (mm 2 ) of the visceral cavity. SAT and VAT densities were defined as the median pixel intensity (HU) of fat-intensity pixels within the subcutaneous and visceral regions, respectively. The DMG perimeter area (mm 2 ) was defined as the boundary built from the triangle between the spinal canal and the left and right lateral borders of the DMG, connected by the nearest location to the posterior fascial envelope, irrespective of bone, muscle or air contents. The DMG perimeter mean density included the mean pixel intensity (HU) within the DMG perimeter area. The DMG normal density muscle area was defined as the cross-sectional area (mm 2 ) of the pixels within the DMG perimeter area falling in a normal density muscle HU range (31-100 HU). 1 Statistical analyses were performed using R 3.20 (http://www. r-project.org), with α = 0.05 defining the level of statistical significance (two sided). The morphomic variables were dichotomized into 'low' vs 'high' groups based on their median values. Univariate regression methods (competing risks regression for relapse, acute GVHD and non-relapse mortality (NRM) and Cox regression for disease-free survival (DFS) and overall survival) were used to model the associations for patient, disease, transplant and morphomic variables with clinical outcomes. The Fine-Gray method was used to determine cumulative incidences with competing risks (competing risks regression). 9 Kaplan-Meier method and Cox's proportional model were used to assess overall survival (Cox regression). 10 Multivariate regression methods were then applied to identify factors independently associated with clinical outcomes. To assess for potential confounding, all candidate predictors from the univariate analysis were entered into the regression analysis, and forward-backward stepwise selection by the Akaike Information Criterion 11 was used to identify the best-fitting models.
The median age of the study population (N = 256) was 50 years (interquartile range (IQR) 27-58 years), comprised predominantly of adults (⩾18 years, 91%), males (59%) and Caucasians (92%). The median body mass index was 27 kg/m 2 (IQR 24, 32 kg/m 2 ). The percentage of intermediate or high comorbidity index (HCT-CI) was 87%, with a median HCT-CI of 3 (IQR 2, 5).
HLA-mismatched or unrelated donors increased the risk of grades 2-4 acute GVHD at day 100 compared with HLA-matched or related donors (66% vs 38%, P o0.001 and 54% vs 30%, Po 0.001). High (above the median) VAT and SAT area were both significantly associated with increased risk of grades 2-4 acute GVHD compared with low (below the median) VAT and SAT area (52% vs 36%, P o0.001 and 50% vs 38%, P = 0.005, respectively) (Table 1A) . Similarly, high fascia area was associated with increased risk of grades 2-4 acute GVHD (49% vs 38%, P = 0.01). However, in adjusted models, while high VAT area remained significantly associated with grades 2-4 acute GVHD (hazard ratio (HR) 1.33, 95% confidence interval (CI): 1.13, 1.57, P o 0.001), the other morphomic variables were not (Table 1B) .
Related donor (34% vs 14%, P o0.001) and myeloablative conditioning regimen (26% vs 17%, P = 0.02) increased the risk of 1-year relapse (Table 1A) and remained as significant predictors even after adjusting for potential confounders (Table 1B) . Low fascia area was the only morphomic variable in the univariate analysis that was associated with increased risk for 1-year relapse (28% vs 17%, P = 0.005, Table 1A ) and remained significant in the adjusted model (HR 0.65, 95% CI: 0.48, 0.87, P = 0.004, Younger age, male gender, unrelated donor and myeloablative conditioning regimen were associated with increased risk for 1-year NRM (7% vs 2%, P = 0.005; 9% vs 2%, P = 0.004; 8% vs 4%, P = 0.05; 8% vs 3%, P = 0.03; respectively). High fascia area was the only morphomic variable associated with increased risk for 1-year NRM compared with low fascia area (9% vs 3%, P = 0.008, Table 1A ). After adjusting for potential confounders, male gender (HR 2.11, 95% CI: 0.78, 5.70, P = 0.14) and SAT area (HR 0.49, 95% CI: 0.27, 0.88, P = 0.02) were the only two variables that predicted the cumulative incidence of NRM (Table 1B) .
HLA-mismatched donor grafts and intermediate and high HCT-CI were associated with decreased DFS at 1-year (41% vs 48%, P = 0.04 and 42% vs 53%, P = 0.001, respectively, Table 1A ). VAT density and SAT density (HU) morphomic variables were also associated with inferior DFS at 1-year (43% vs 50%, P = 0.03, 41% vs 52%, P o 0.001, respectively, Abbreviations: aGVHD = acute GVHD; DFS = disease-free survival; DMG = dorsal muscle group; HCT-CI = Hematopoietic Cell Transplantation-Specific Comorbidity Index; HU = Hounsfield Units; ND = normal density; NRM = non-relapse mortality; OS = overall survival; SAT = subcutaneous adipose tissue; VAT = visceral adipose tissue. P = 0.06, Table 1B ), as did VAT and SAT areas (HR 1.20, 95% CI: 0.96, 1.50, P = 0.10 and HR 1.30, 95% CI: 1.01, 1.68, P = 0.04, respectively, Table 1B ). When we examined muscle quality, both high DMG normal density area and DMG HU correlated with significantly improved DFS at 1-year (50% vs 43%, P = 0.01 and 50% vs 43%, P = 0.01, respectively, Table 1A ), and after adjusting for potential confounders, DMG HU remained in the final model for DFS (HR 0.85, 95% CI: 0.70, 1.03, P = 0.09). Similar correlations with the morphomic variables were observed when we examined overall survival as an outcome. To our knowledge, this is the first study to examine radiographic characteristics of adipose tissue and muscle attenuation with regards to clinical outcomes in the setting of allogeneic HCT, based on a novel framework developed by the Morphomic Analysis Group. [1] [2] [3] [4] The novel methodology of analytic morphomics was employed to quantify adipose tissue and muscle composition and correlate with clinical outcomes. There were three principal findings of our work: (1) Higher VAT and SAT areas were associated with shorter DFS; (2) Higher VAT and SAT density also conveyed a correlation with inferior DFS, although these relations were more convincing for VAT density after controlling for potential confounders; (3) Increased DMG density (HU) was associated with improved DFS. Similar correlations were seen with overall survival. Taken together, these findings suggest that increased levels of dense adipose tissue and poor quality muscle composition may be associated with adverse survival outcomes in patients undergoing allogeneic HCT independent of known risk factors. Further investigation into the longitudinal interrelationship between adipose tissue and muscle composition is worth exploring as a means to determine whether changes can be detected over time that would allow for effective interventions to be made early on.
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